Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Investigator Initiated Study to Evaluate the Safety, Tolerability and Preliminary Effectiveness of AB-SA01 in Patients with Chronic Rhinosinusitis Associated with Staphylococcus aureus Infection

Next Previous
X
Search
Trial Profile

A Phase 1 Investigator Initiated Study to Evaluate the Safety, Tolerability and Preliminary Effectiveness of AB-SA01 in Patients with Chronic Rhinosinusitis Associated with Staphylococcus aureus Infection

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AP SA01 (Primary)
  • Indications Rhinosinusitis; Staphylococcal infections
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 04 Apr 2017 According to an AmpliPhi Biosciences Corporation media release, data from this trial will be presented at the 2017 Australian Society of Otolaryngology Head and Neck Surgery Meeting.
    • 19 Dec 2016 According to an AmpliPhi Biosciences Corporation media release, detailed results from this trial will be presented at a medical conference in 2017.
    • 19 Dec 2016 Results published in an AmpliPhi Biosciences Corporation media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top